文献速递心脑血管急症复苏、休克与脓毒症

神经科急症中经外周静脉快速推注3%高渗盐水的安全性

Safety of peripheral 3% hypertonic saline bolus administration for neurologic emergency.
PubMed 文献 · Am J Emerg Med · 2023-04-10
一句话结论回顾性队列显示,神经科急症患者经外周静脉以中位760 mL/h(最高999 mL/h)快速推注3%高渗盐水,未发生外渗或静脉炎。

本研究为回顾性队列研究,纳入2018年5月5日至2021年9月30日期间因颅内压升高、脑水肿或其他神经科急症经外周静脉以≥250 mL/h速率接受3%高渗盐水的成人患者,排除同时接受其他高渗盐水者。共筛查206例,37例符合标准,最常见排除原因为输注速率<250 mL/h。中位年龄60岁(IQR 45,72),男性51.4%;最常见适应证为创伤性脑损伤(45.9%)和颅内出血(37.8%),最常见给药地点为急诊科(78.4%)。中位剂量250 mL(IQR 250,350),中位速率760 mL/h(IQR 500,999),无外渗或静脉炎发生。作者认为,快速经外周静脉推注3%高渗盐水是神经科急症的安全替代方案。

要点

  • 37例神经科急症成人经外周静脉以中位760 mL/h(IQR 500,999)推注3%高渗盐水,未发生外渗或静脉炎。
  • 最常见适应证为创伤性脑损伤(45.9%)和颅内出血(37.8%),78.4%在急诊科给药。
  • 中位剂量250 mL(IQR 250,350),中位静脉留置针型号18G(IQR 18,20),最常见置管部位为肘前(48.6%)。
  • 作者认为,经外周静脉快速推注3%高渗盐水(速率最高达999 mL/h)是神经科急症的安全替代方案。

适用人群与场景

  • 因颅内压升高、脑水肿或其他神经科急症经外周静脉接受3%高渗盐水的成人患者。
  • 排除同时接受其他高渗盐水液体的患者。

研究设计与关键结果

  • 研究类型:回顾性队列研究;筛查206例,最终纳入37例符合标准的成人患者。
  • 最常见排除原因为输注速率<250 mL/h。
  • 中位年龄60岁(IQR 45,72),男性占51.4%。
  • 最常见适应证:创伤性脑损伤45.9%,颅内出血37.8%。
  • 最常见给药地点:急诊科78.4%。
  • 中位静脉留置针型号18G(IQR 18,20,n=29),最常见置管部位为肘前(48.6%)。
  • 中位剂量250 mL(IQR 250,350),中位给药速率760 mL/h(IQR 500,999)。
  • 主要安全性结局:给药后1小时内无外渗或静脉炎发生。

证据类型、等级与局限

  • 证据类型:回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,经外周静脉快速推注3%高渗盐水(速率最高达999 mL/h)是神经科急症的安全替代方案。
  • 作者指出,速率最高达999 mL/h未导致外渗或静脉炎。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND/OBJECTIVE: Hypertonic sodium chloride (HTS) is used for emergent treatment of acute cerebral edema and other neurologic emergencies. Central access is not commonly available in emergent situations and 3% HTS is utilized peripherally. Many studies have shown the safety of its administration at rates up to 75 mL/h, but there is a lack of data to establish the safety of peripherally administered, rapid bolus dosing in emergent situations. The objective of this study is to describe the safety of rapid, peripherally administered (≥ 250 mL/h) 3% HTS for neurologic emergencies.

METHODS: This is a retrospective, cohort study including adult patients receiving 3% HTS via a peripheral IV site for elevated intracranial pressure, cerebral edema, or other neurological emergencies at a rate of at least 250 m/h between May 5, 2018 - September 30, 2021. Patients were excluded if they simultaneously received another hypertonic saline fluid. Baseline characteristics collected included HTS dose, rate and site of administration, indication for use and patient demographics. The primary safety outcome was incidence of extravasation and phlebitis within one hour of HTS administration.

RESULTS: There were 206 patients receiving 3% HTS who were screened, and 37 patients met inclusion criteria. The most common reason for exclusion was administration at a rate < 250 m/h. The median age was 60 (IQR 45, 72) with 51.4% being male. The most common indications for HTS were traumatic brain injury (45.9%) and intracranial hemorrhage (37.8%). The most common administration location was the emergency department (78.4%). The median IV-gauge (n = 29) was 18 (IQR 18, 20), with the most common placement site being antecubital (48.6%). The median dose of HTS was 250 mL (IQR 250, 350), with a median administration rate of 760 mL/h (IQR 500, 999). There were no episodes of extravasation or phlebitis noted.

CONCLUSIONS: Rapid, peripheral administration of 3% HTS boluses is a safe alternative for treatment of neurologic emergencies. Administration at rates up to 999 mL/h did not result in extravasation or phlebitis.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Brown CS, Rabinstein AA, Zhao Y, et al. Safety of peripheral 3% hypertonic saline bolus administration for neurologic emergency. Am J Emerg Med. 2023. PMID: 37079938. doi:10.1016/j.ajem.2023.04.007

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。